Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Scinopharm Aims To Launch Drug In China

by Jean-François Tremblay
November 17, 2014 | A version of this story appeared in Volume 92, Issue 46

ScinoPharm, a Taiwanese pharmaceutical chemical maker, will work with Nanjing King-friend Biochemical Pharmaceutical to launch a version of regadenoson in China. Sold in the U.S. by Astellas Pharma as Lexiscan, regadenoson is used in stress tests of patients who can’t undergo exercise-based stress. ScinoPharm will develop and produce the active ingredient for regadenoson and King-friend will manage the sterile-injection product and regulatory applications. The companies see a potential market in China of up to $50 million per year.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.